IPS Examines How Uganda’s Anti-Counterfeit Bill Could Impact Access To Generic Drugs

Inter Press Service examines Uganda’s “controversial Counterfeit Goods Bill,” which some say will limit the public’s access to “life-saving generic medicines.”

According to the news service, Gagawala Wambuzi, Uganda’s trade minister “who is spearheading the bill,” recently defended the bill as a means of protecting the country’s industry from counterfeiters, but he agreed the bill should not restrict the manufacturing or importation of generic drugs.

Still, groups are calling for the bill to be redrafted. Uganda’s Registration Services Bureau, for instance, “believes the bill should be redrafted specifically only fill the gaps in the existing [intellectual property] legal frameworks in the Copyright Act and Trademarks Act,” IPS writes, adding that similar counterfeit measures adopted in Kenya and Tanzania could threaten the production of generic medicines (Michael, 4/29).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.